Update on human papillomavirus vaccines for cervical cancer

Current Opinion in Investigational Drugs

Volumn 3, Issue 1, 2002, Pages 37-47

  Steller, Michael A ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Cervical cancer; Dendritic cells; Human papillomavirus vaccine; T cells; Viral vectors; Virus like particles

Indexed keywords

CAPSID PROTEIN; HEAT SHOCK PROTEIN 65 HUMAN PAPILLOMA VIRUS 16 E7; HUMAN PAPILLOMA VIRUS 16 E6 PLUS E7; HUMAN PAPILLOMA VIRUS 16 E7; HUMAN PAPILLOMA VIRUS 16 L2E7; IMMUNOSTIMULATING AGENT; ISCOM; ISCOMATRIX; NAKED DNA; NEUTRALIZING ANTIBODY; NUCLEIC ACID; ONCOPROTEIN; ONCOPROTEIN HUMAN PAPILLOMA VIRUS 16; ONCOPROTEIN HUMAN PAPILLOMA VIRUS 18; PEPTIDE DERIVATIVE; PROTEIN E6; PROTEIN E7; PROVAX; RECOMBINANT ADENOVIRUS VACCINE; RECOMBINANT DNA; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT VACCINE; SAPONIN; SIG PLUS E7 PLUS LYSOSOMAL ASSOCIATED MEMBRANE PROTEIN 1; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ANTIGEN; VIRUS FUSION PROTEIN; VIRUS VACCINE; VIRUS VECTOR; PAPILLOMA VIRUS VACCINE;

CANCER MORTALITY; CANCER SCREENING; CELLULAR IMMUNITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; NONHUMAN; PROPHYLAXIS; REVIEW; SEXUALLY TRANSMITTED DISEASE; TOXICITY; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS INFECTION; VIRUS PARTICLE; WART VIRUS; ANIMAL; GENE THERAPY; IMMUNOLOGY; METHODOLOGY; PAPILLOMA VIRUS; UTERINE CERVIX TUMOR; VIROLOGY;

ANIMAL; CERVIX NEOPLASMS; FEMALE; GENE THERAPY; HUMAN; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS, HUMAN; TUMOR VIRUS INFECTIONS; VIRAL VACCINES; ANIMALS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 0035985620     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Estimates of the worldwide mortality from 25 cancers in 1990
2. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop
3. Estimates of the incidence of prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel
4. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group
5. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
6. Heterogeneity of the human papillomavirus group
7. Differential effects of human papillomavirus type 6, 16 and 18 DNAs on immortalization and transformation of human cervical epithelial cells
8. In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential
9. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products
10. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product
11. Papillomaviridae: The viruses and their replication
12. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: Consequences for the phenotype and E6-p53 and E7-pRB interactions
13. Behavior of mild cervical dysplasia during long-term follow-up
14. Human immunodeficiency virus infection and cervical neoplasia
15. Specific types of human papillomavirus found in benign proliferations and carcinoma of the skin in immunosuppressed patients
16. Association between HLA-expression and infiltration of immune cells in cervical carcinoma
17. Epidemiology of cervical human papillomaviruses
18. Cell biology of antigen presentation
19. DNA-mediated immunization and the energetic immune response to hepatitis B surface antigen
20. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group
21. Papillomavirus vaccines: Current status and future prospects
22. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice
23. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
24. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
25. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
26. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
27. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection
28. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
29. Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse
30. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition
31. Divergent human papillomavirus type 16 variants are serologically cross-reactive
32. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast
33. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice
34. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions
35. H. HPV6b virus like particles are potent immunogens without adjuvant in man
36. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides
37. Genetically engineered tumor vaccines
38. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes
39. Lessons from T cell responses to virus induced tumours for cancer eradication in general
40. Cells involved in the immune response
41. Dendritic cells: Antigen presentation, accessory function and clinical relevance
42. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts
43. Induction of antitumor immunity using bone marrow-generated dendritic cells
44. Immunology taught by viruses
45. Immunotherapy for cancer
46. The next wave of recombinant and synthetic anticancer vaccines
47. Distribution of HLA antigens in North American Caucasians, North American blacks and orientals
48. Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of candidate T-cell epitopes in human papilloma virus
49. Synthetic peptides of human papillomavirus type 18 E6 harboring HLA-A2.1 motif can induce peptide-specific cytotoxic T-cells from peripheral blood mononuclear cells of healthy donors
50. Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection
51. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins
52. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
53. Generation of tumor specific cytolytic T-lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic HPV-16 E7 epitope
54. Cell mediated immunologic responses in cervical and vaginal cancer patients with a lipidated epitope of HPV-16 E7
55. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial
56. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
57. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive
58. Frequency of downregulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression
59. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
60. Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma
61. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter
62. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
63. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors
64. The new vaccines: Building viruses that elicit antitumor immunity
65. Heteroclitic immunization induces tumor immunity
66. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
67. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans
68. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides
69. Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine
70. The ISCOM antigen-presenting system
71. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production
72. ISCOMs (immunostimulating complexes): The first decade
73. Sensitization of MHC class I-restricted T cells to exogenous proteins: Evidence for an alternative class I-restricted antigen presentation pathway
74. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens
75. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16
76. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX
77. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens
78. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7
79. Cervical cancer vaccines: Emerging concepts and developments
80. Phase I safety and antigenicity of TA-GW: A recombinant HPV6 L2E7 vaccine for the treatment of genital warts
81. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts
82. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
83. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection
84. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway
85. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes
86. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice
87. Human papillomavirus type 16 E7 DNA vaccine: Mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity
88. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors
89. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs
90. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene
91. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine
92. Cancer therapy using a self-replicating RNA vaccine
93. Vaccinia virus: A selectable eukaryotic cloning and expression vector
94. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7
95. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector
96. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer
97. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL
98. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens
99. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
100. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein
101. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
102. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16
103. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion
104. The dendritic cell system and its role in immunogenicity
105. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
106. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
107. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
108. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity
109. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
110. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells
111. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer
112. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity
113. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo
114. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: Implications for cervical cancer immunotherapy
115. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
116. Epidemiology of human papilloma virus infections and genital neoplasia
117. Epidemiology of genital human papillomavirus infection
118. Cervical cancer
119. Epidemiology of cervical cancer. Overview
120. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden